Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biotech company currently trading at $7.43 and identified as undervalued by InvestingPro analysts, has initiated dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 for chronic hepatitis B virus (HBV) infection, the company announced Wednesday.
The randomized, double-blind study will evaluate ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated adult subjects with chronic HBV infection over 48 weeks. The trial will assess safety, efficacy, pharmacokinetics, and various biomarkers of HBV infection. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.31, suggesting adequate resources to support its clinical programs.
"Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos," said Lawrence Blatt, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
Nezam Afdhal, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center, noted that despite available treatments for chronic HBV infection, better therapies are needed to prevent progression to end-stage liver disease and liver cancer.
ALG-000184 is an oral small molecule capsid assembly modulator being developed for chronic HBV. Phase 1 studies showed the drug was well-tolerated with no safety signals observed, and demonstrated antiviral activity.
The company expects interim data from the B-SUPREME study in 2026, with topline data anticipated in 2027.
Chronic HBV infection affects approximately 254 million patients worldwide and is the primary cause of liver cancer globally, according to information provided in the company’s press release statement. With a market capitalization of $45.74 million and strong cash position relative to debt, Aligos appears positioned to pursue this significant market opportunity. For deeper insights into Aligos’s financial health and growth prospects, including 12 additional ProTips, visit InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.